Jangan menggunakan Meprothion yang telah melewati tanggal kedaluwarsa
Semaglutide activates GLP-1 receptors throughout the brain and body, triggering metabolic shifts that can temporarily reduce energy levels
Research has revealed that GLP-1 agonist medications work, in part, by suppressing appetite signaling in the brain
Contact your GP or prescribing clinician if you experience : Severe or worsening fatigue that significantly impairs daily activities or persists beyond several weeks of treatment Extreme weakness or inability to perform usual tasks Dizziness or fainting , particularly on standing, which may indicate dehydration or blood pressure changes Persistent nausea or vomiting preventing adequate food or fluid intake Signs of dehydration : dark urine, reduced urination, dry mouth, confusion Chest pain, palpitations, or breathlessness accompanying tiredness Mood changes , including low mood or depression, which can manifest as fatigue Right upper abdominal pain, fever or yellowing of the skin/eyes , which could indicate gallbladder problems (GLP-1 medications may increase gallstone risk) For urgent but non-emergency concerns, you can contact NHS 111 for advice
MicroRNA-150 (miR-150) and diabetic retinopathy: is miR-150 only a biomarker or does it contribute to disease progression
Doctors typically recommend staying on the current dose for 6 weeks to determine if any issues develop before increasing the dose